AVIR

Atea Pharmaceuticals Inc

Jul 16 • 04:00PM ET

3.49

Dollar change -0.08
Percentage change -2.24	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA GILD BNTX JNJ NVAX VXRT RIGL PTGX CYCN

| Held by: VTI IWM VXF IWN IBB VTWO SCHA DFAT ITOT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.65	Insider Own	18.96%	Shs Outstand	85.58M	Perf Week	-7.18%
Market Cap	298.67M	Forward P/E	-	EPS next Y	-1.71	Insider Trans	0.00%	Shs Float	69.36M	Perf Month	10.44%
Enterprise Value	-125.32M	PEG	-	EPS next Q	-0.41	Inst Own	59.38%	Short Float	5.49%	Perf Quarter	18.71%
Income	-139.49M	P/S	-	EPS this Y	-8.50%	Inst Trans	-6.68%	Short Ratio	8.58	Perf Half Y	9.06%
Sales	0.00M	P/B	0.73	EPS next Y	21.20%	ROA	-28.09%	Short Interest	3.81M	Perf YTD	4.18%
Book/sh	4.80	P/C	0.70	EPS next 5Y	12.39%	ROE	-30.47%	52W High	4.14 -15.80%	Perf Year	1.75%
Cash/sh	4.97	P/FCF	-	EPS past 3/5Y	- -63.72%	ROIC	-33.88%	52W Low	2.45 42.16%	Perf 3Y	-55.43%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.59% 4.22%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	15.73%	Oper. Margin	-	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.94	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.35	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	19.94	EPS Q/Q	46.55%	SMA20	-1.29%	Beta	0.25	Target Price	6.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	9.55%	Rel Volume	1.72	Prev Close	3.57
Employees	56	LT Debt/Eq	0.00	Earnings	May 14 BMO	SMA200	9.86%	Avg Volume	443.82K	Price	3.49
IPO	Oct 30, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	20.52% -	Trades		Volume	763,561	Change	-2.24%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$2 → $6.88
Aug-10-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$14 → $7
Nov-18-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-20-21	Downgrade	JP Morgan	Overweight → Neutral	$61 → $16
Oct-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$55
Nov-25-20	Initiated	Evercore ISI	Outperform
Nov-24-20	Initiated	William Blair	Outperform	$60
Nov-24-20	Initiated	Morgan Stanley	Overweight	$49
Nov-24-20	Initiated	JP Morgan	Overweight	$45

Jun-24-25 07:00AM	Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America (GlobeNewswire)
May-12-25 04:11PM	Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.82% -11.15%
May-07-25 07:00AM	Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 (GlobeNewswire)
May-01-25 07:00AM	Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 (GlobeNewswire)
Apr-23-25 07:00AM	Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 (GlobeNewswire)
07:00AM	Loading…
Apr-17-25 07:00AM	Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program (GlobeNewswire)
Apr-09-25 07:00AM	Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (GlobeNewswire)
Mar-26-25 01:58PM	Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value (GlobeNewswire)
08:00AM	The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors (Business Wire)
Mar-21-25 05:54PM	Atea Pharmaceuticals Issues Statement Regarding Director Nominations (GlobeNewswire)
08:25AM	Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory (InsiderMonkey)
Mar-19-25 07:00AM	Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025 (GlobeNewswire)
Mar-07-25 12:46PM	Q4 2024 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:17AM	Atea Pharmaceuticals Inc (AVIR) Q4 2024 Earnings Call Highlights: Strategic Moves and Promising ... (GuruFocus.com)
Mar-06-25 04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
Feb-27-25 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025 (GlobeNewswire)
Feb-24-25 07:00AM	Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors (GlobeNewswire)
Jan-13-25 07:00AM	Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-25 07:00AM	Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 05:05PM	Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process (Business Wire)
Dec-16-24 05:00AM	Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships (GlobeNewswire) +5.80%
Dec-05-24 07:06AM	Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir (TipRanks) -5.94%
Dec-04-24 03:14PM	After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study (Benzinga) -10.49%
07:00AM	Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV) (GlobeNewswire)
06:09AM	Atea plans Phase 3 study for hepatitis C drug after mid-stage results (BioPharma Dive)
Nov-26-24 07:00AM	Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-22-24 09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-15-24 11:00AM	Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 (GlobeNewswire)
Nov-11-24 08:01PM	Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com)
Nov-07-24 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
Oct-31-24 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (GlobeNewswire)
Oct-30-24 07:00AM	Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 (GlobeNewswire)
Oct-16-24 09:40AM	Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? (Zacks) +6.20%
Oct-09-24 05:19PM	Atea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
Oct-04-24 09:35AM	Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-30-24 09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-13-24 02:53PM	Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus (Benzinga) +5.45%
07:00AM	Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 (GlobeNewswire)
Aug-28-24 09:40AM	Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? (Zacks)
07:00AM	Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway (GlobeNewswire)
Aug-12-24 12:00PM	All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy (Zacks)
09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-07-24 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +7.03%
Jul-31-24 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 (GlobeNewswire)
Jun-05-24 07:00AM	Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 (GlobeNewswire) +5.04%
May-29-24 07:00AM	Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-22-24 07:00AM	Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 (GlobeNewswire) +5.82%
May-15-24 09:01AM	Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ... (GuruFocus.com) -6.31%
May-14-24 04:05PM	Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 07:00AM	Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024 (GlobeNewswire)
Apr-29-24 07:00AM	Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 (GlobeNewswire)
Mar-27-24 07:00AM	Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients (GlobeNewswire) +6.10%
Feb-29-24 10:03AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:58PM	Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-21-24 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 (GlobeNewswire)
Jan-10-24 09:30AM	Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study (Zacks)
Jan-08-24 04:05PM	Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19 (GlobeNewswire) +11.29%
Jan-03-24 07:00AM	Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-13-23 07:00AM	Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 03:57PM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript (Insider Monkey) -9.12%
05:48AM	Q3 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Nov-02-23 07:00AM	Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-01-23 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023 (GlobeNewswire) -5.23%
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Sep-06-23 07:00AM	Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-09-23 06:58AM	Q2 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023 (GlobeNewswire)
Jun-15-23 07:00AM	Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination (GlobeNewswire)
Jun-05-23 04:20PM	Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 07:00AM	Atea Pharmaceuticals Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners Affiliate, Concentra Biosciences (GlobeNewswire) -11.97%
May-26-23 07:02PM	Lordstown Motors and Atea Pharmaceuticals Stock See Action From Activist Investors (Barrons.com)
May-23-23 04:05PM	Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners Affiliate, Concentra Biosciences (GlobeNewswire)
May-10-23 11:53AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-09-23 10:09AM	Q1 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 04:05PM	Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-01-23 04:05PM	Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023 (GlobeNewswire)
Apr-25-23 07:00AM	Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19 (GlobeNewswire)
Apr-12-23 07:00AM	Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases (GlobeNewswire)
Mar-14-23 07:00AM	New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research (GlobeNewswire) +7.72%
Mar-08-23 07:00AM	New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research (GlobeNewswire)
Mar-02-23 09:20PM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2022 Earnings Call Transcript (Insider Monkey) +5.54%
Feb-28-23 04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) -8.19%
Feb-23-23 07:00AM	Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023 (GlobeNewswire)
Feb-21-23 07:00AM	Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023 (GlobeNewswire) -5.41%
Feb-15-23 04:05PM	Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections (GlobeNewswire)
Feb-13-23 08:22AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is a favorite amongst institutional investors who own 62% (Simply Wall St.)
Feb-07-23 07:00AM	Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-09-23 07:00AM	Atea Pharmaceuticals Highlights Strategic Priorities for 2023 (GlobeNewswire)
Jan-04-23 07:00AM	Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-22 11:10AM	Boston biotech retools Covid drug to make 'next generation of Paxlovid' (American City Business Journals) +5.01%
Nov-29-22 07:00AM	Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19 (GlobeNewswire)
Nov-22-22 07:00AM	Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-19-22 09:46AM	Atea Pharmaceuticals (NASDAQ:AVIR) shareholders have endured a 42% loss from investing in the stock a year ago (Simply Wall St.)
Nov-10-22 12:00PM	Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade (Zacks) +7.59%
09:35AM	After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR) (Zacks)
Nov-08-22 04:05PM	Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -9.88% -10.40%

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Murphy Polly A.	Director	Jun 20 '25	Option Exercise	0.00	29,600	0	86,045	Jun 24 06:05 PM
BERGER FRANKLIN M	Director	Jun 20 '25	Option Exercise	0.00	29,600	0	506,497	Jun 24 06:05 PM
Duncan Barbara Gayle	Director	Jun 20 '25	Option Exercise	0.00	29,600	0	62,750	Jun 24 06:05 PM
Polsky Bruce	Director	Jun 20 '25	Option Exercise	0.00	29,600	0	95,206	Jun 24 06:05 PM
Adams Jerome M.	Director	Jun 20 '25	Option Exercise	0.00	29,600	0	62,750	Jun 24 06:05 PM
Lucidi Bruno	Director	Jun 20 '25	Option Exercise	0.00	29,600	0	112,750	Jun 24 06:05 PM
BERGER FRANKLIN M	Director	Dec 10 '24	Sale	2.85	359,606	1,023,475	451,897	Dec 12 06:00 PM
Franklin Berger	Lead Independent Director	Dec 10 '24	Proposed Sale	2.85	359,606	1,023,475		Dec 10 05:17 PM
Sommadossi Jean-Pierre	President, CEO, and Chairman	Sep 17 '24	Sale	4.05	33,941	137,318	5,890,053	Sep 19 08:02 PM
Sommadossi Jean-Pierre	President, CEO, and Chairman	Sep 18 '24	Sale	4.03	22,187	89,469	5,867,866	Sep 19 08:02 PM
Sommadossi Jean-Pierre	President, CEO, and Chairman	Sep 19 '24	Sale	4.00	1,841	7,367	5,866,025	Sep 19 08:02 PM
JPM Partners LLC	Affiliate	Sep 19 '24	Proposed Sale	4.00	1,841	7,367		Sep 19 04:22 PM
JPM Partners LLC	Affiliate	Sep 18 '24	Proposed Sale	4.03	22,187	89,469		Sep 18 04:09 PM
JPM Partners LLC	Affiliate	Sep 17 '24	Proposed Sale	4.05	33,941	137,318		Sep 17 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVIR

Atea Pharmaceuticals Inc

Upgrade your FINVIZ experience